PMEF
PRQR icon

Point72 Middle East FZE’s ProQR Therapeutics PRQR Stock Holding History

Point72 Middle East FZE’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,252
Closed -$11.2K – 1975
2023
Q1 		$11.2K Buy
+5,252
New +$16.1K ﹤0.01% 1478

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 Middle East FZE's PRQR Position: Q2 2023 in Review

Point72 Middle East FZE sold out of ProQR Therapeutics (PRQR) in Q2 2023, closing a stake of 5,252 shares — an estimated $11.2K sold.

Point72 Middle East FZE first reported a position in PRQR in Q1 2023 and held it in 1 quarter. The position peaked at $11.2K in Q1 2023. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2023.

  • Point72 Middle East FZE reported no remaining ProQR Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,252 ProQR Therapeutics shares in Q2 2023, an estimated $11.2K.
  • Point72 Middle East FZE first reported a position in ProQR Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's ProQR Therapeutics position peaked at $11.2K in Q1 2023.
  • 51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.